Michelle D. Hackshaw

2.5k total citations
30 papers, 438 citations indexed

About

Michelle D. Hackshaw is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Michelle D. Hackshaw has authored 30 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 13 papers in Economics and Econometrics. Recurrent topics in Michelle D. Hackshaw's work include Renal cell carcinoma treatment (14 papers), Economic and Financial Impacts of Cancer (13 papers) and HER2/EGFR in Cancer Research (7 papers). Michelle D. Hackshaw is often cited by papers focused on Renal cell carcinoma treatment (14 papers), Economic and Financial Impacts of Cancer (13 papers) and HER2/EGFR in Cancer Research (7 papers). Michelle D. Hackshaw collaborates with scholars based in United States, United Kingdom and Japan. Michelle D. Hackshaw's co-authors include Saurabh Nagar, Jasmeet Singh, Jose Diaz, Mary E. Ritchey, Heather E. Danysh, Keith C. Deen, Corina Taitt, Charles A. Powell, Hiroji Iwata and D. Ross Camidge and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Statistical Association and Cancer.

In The Last Decade

Michelle D. Hackshaw

29 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle D. Hackshaw United States	15	282	221	121	118	50	30	438
Emmanuelle Kempf France	12	200 0.7×	206 0.9×	59 0.5×	175 1.5×	91 1.8×	56	536
Katherine B. Winfree United States	14	407 1.4×	384 1.7×	77 0.6×	56 0.5×	85 1.7×	55	613
Nathan C. Nussbaum United States	11	332 1.2×	397 1.8×	73 0.6×	89 0.8×	154 3.1×	22	635
S. Swann United States	13	359 1.3×	315 1.4×	38 0.3×	229 1.9×	41 0.8×	33	696
A.L. Vataire France	13	170 0.6×	157 0.7×	114 0.9×	68 0.6×	158 3.2×	34	478
Xiaofei F. Wang United States	14	254 0.9×	283 1.3×	82 0.7×	150 1.3×	39 0.8×	31	638
Melissa D. Curtis United States	6	217 0.8×	258 1.2×	68 0.6×	45 0.4×	78 1.6×	8	427
Paul You United States	6	191 0.7×	241 1.1×	55 0.5×	42 0.4×	94 1.9×	8	412
Pasquale Lombardi Italy	12	154 0.5×	243 1.1×	53 0.4×	123 1.0×	111 2.2×	43	505
Melisa Tucker United States	9	301 1.1×	357 1.6×	86 0.7×	52 0.4×	123 2.5×	13	566

Countries citing papers authored by Michelle D. Hackshaw

Since Specialization

Citations

This map shows the geographic impact of Michelle D. Hackshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle D. Hackshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle D. Hackshaw more than expected).

Fields of papers citing papers by Michelle D. Hackshaw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle D. Hackshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle D. Hackshaw. The network helps show where Michelle D. Hackshaw may publish in the future.

Co-authorship network of co-authors of Michelle D. Hackshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle D. Hackshaw. A scholar is included among the top collaborators of Michelle D. Hackshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle D. Hackshaw. Michelle D. Hackshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Denduluri, Neelima, et al.. (2022). Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Drugs - Real World Outcomes. 10(2). 177–186. 1 indexed citations

Mansfield, Carol, et al.. (2022). Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study. Breast Cancer. 30(1). 23–35. 3 indexed citations

Salas, Maribel, et al.. (2022). Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer. 22(1). 66–66. 18 indexed citations

Perez, Edith A., Chau T. Dang, Caleb Lee, et al.. (2022). Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Research and Treatment. 194(1). 1–11. 16 indexed citations

Hackshaw, Michelle D., Heather E. Danysh, Nora Tu, et al.. (2021). Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer. 21(1). 967–967. 28 indexed citations

Cella, David, Michelle D. Hackshaw, L. Michelle Bennett, et al.. (2021). Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.. Journal of Clinical Oncology. 39(15_suppl). 4057–4057. 5 indexed citations

Hackshaw, Michelle D., Heather E. Danysh, Jasmeet Singh, et al.. (2020). Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 183(1). 23–39. 66 indexed citations

Powell, Charles A., D. Ross Camidge, Shanu Modi, et al.. (2020). 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Annals of Oncology. 31. S357–S358. 18 indexed citations

Hackshaw, Michelle D., et al.. (2020). Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumabPost-Trastuzumab Gastric Cancer. Cancer Treatment and Research Communications. 24. 100189–100189. 2 indexed citations

10.

Hackshaw, Michelle D., et al.. (2016). Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States. Clinical Genitourinary Cancer. 14(5). e479–e487. 4 indexed citations

11.

Jiao, Xiaolong, Thomas W. Wilson, Michelle D. Hackshaw, et al.. (2016). Comparative effectiveness of pazopanib and sunitinib as first-line therapy for patients with advanced/metastatic renal cell carcinoma in a U.S. community oncology setting.. Journal of Clinical Oncology. 34(2_suppl). 567–567. 5 indexed citations

12.

Hackshaw, Michelle D., Ryan N. Hansen, Saurabh Nagar, et al.. (2014). Costs Associated with Health Care Resource Use in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Treatment with Pazopanib Versus Sunitinib. Value in Health. 17(3). A77–A78. 1 indexed citations

13.

Hackshaw, Michelle D., et al.. (2014). Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database. Journal of Managed Care Pharmacy. 20(6). 603–610. 24 indexed citations

14.

Vogelzang, Nicholas J., et al.. (2014). First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clinical Genitourinary Cancer. 13(3). 210–217. 23 indexed citations

15.

Nakhai-Pour, Hamid Reza, et al.. (2014). Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) patients in the United States.. Journal of Clinical Oncology. 32(15_suppl). e17551–e17551.

16.

Beaumont, Jennifer L., Jose Diaz, Keith C. Deen, et al.. (2014). Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN).. Journal of Clinical Oncology. 32(15_suppl). 4581–4581. 2 indexed citations

17.

Hutson, Thomas E., et al.. (2014). Outcomes of Advanced Renal Cell Carcinoma Patients (Arcc) Treated with Mammalian Target of Rapamycin Inhibitor (Mtori) Therapy Following First-Line Pazopanib (Paz) in a Us Community Oncology Setting. Annals of Oncology. 25. iv295–iv295. 1 indexed citations

18.

Hagiwara, May, Michelle D. Hackshaw, & Gerry Oster. (2013). Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. Journal of Medical Economics. 16(11). 1300–1306. 11 indexed citations

19.

Hackshaw, Michelle D., et al.. (2012). Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery. ClinicoEconomics and Outcomes Research. 4. 169–169. 6 indexed citations

20.

Hatfield, Laura A., Mark E. Boye, Michelle D. Hackshaw, & Bradley P. Carlin. (2012). Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros. Journal of the American Statistical Association. 107(499). 875–885. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact